We believe that this combination of assets is fairly unique in the biotechnology industry and explains why we were one of the few companies able to raise a substantial amount of money in recent times.
H1N1 (swine) and other influenza viruses:
As reflected by global events over the Fourth of July holiday, our assets and expertise could prove to be particularly important in battling the H1N1 (swine) flu pandemic. Only last week, Buenos Aires declared a swine flu health emergency amidst escalating morbidity and mortality in the Southern Hemisphere. Argentina's experience in dealing with the winter flu season shows us how challenging our own flu season will likely be this fall and winter, even without the virus getting worse. In the United Kingdom, the country's health secretary said in early July that the U.K. could have more than 100,000 flu cases a day by the end of August. During the weekend, the World Health Organization (WHO) convened a high-level meeting in Cancun, Mexico. At this meeting the WHO's Director General was underscoring the unstoppable nature of swine flu and its potential to mutate - "Constant, random mutation is the survival mechanism of the microbial world. Like all influenza viruses, H1N1 has the advantage of surprise on its side." At the same time, the second and third global cases of Tamiflu-resistant swine flu were reported. Significantly, the third case was reported in a 16-year-old girl (Hong Kong) who was Tamiflu resistant even though she had never been treated with Tamiflu: she was infected with swine flu viruses that already were resistant to Tamiflu.
While it is not yet clear whether the Hong Kong case is a result of resortment (gene-swapping), the advent of Tamiflu-resistant strains of swine flu that have shown the ability to spread is particularly troubling given the rapidly-evolving bird flu situation in one country where public health experts are increasingly co
|SOURCE CEL-SCI Corporation|
Copyright©2009 PR Newswire.
All rights reserved